원문정보
초록
영어
Early diagnosis and appropriate treatment can significantly lower the death rate from cancer, so the discovery of low-cost and high-efficiency cancer biomarkers for early diagnosis of cancer has been ongoing for a long time. However, most biomarkers based on quantitative differences are not limited to specific cancers and have inconsistent reproducibility, so they are used as an auxiliary form of diagnosis. Accordingly, we tried to discover biomarkers with improved diagnostic ability by considering not only quantitative differences but also qualitative differences, that is, changes in glycosylation. Protein X, which was confirmed to have a specific glycosylation structure in liver cancer patients through our previous study, was selected as a target protein, and its potential as a liver cancer biomarker was investigated through quantitative and qualitative analysis. In particular, to analyze the glycosylation pattern of protein X, an aglycosylated antibody-based lectin-coupled immunoassay was introduced and verified. As a result of analyzing the patient's clinical samples through this method, it was confirmed that the fucosylation pattern of protein X was similar to that of AFP, which the FDA approved as a biomarker. Therefore, the fucosylation of protein X is expected to have potential as a liver cancer biomarker.